Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap)  (beta) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer) Overgo Probe Designer
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:oxazinane
go back to main search page
Accession:CHEBI:46952 term browser browse the term
Synonyms:related_synonym: oxazinanes


show annotations for term's descendants           Sort by:
(S)-timolol (anhydrous) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adrb1 adrenoceptor beta 1 multiple interactions ISO Timolol binds to and results in decreased activity of ADRB1 protein; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] CTD PMID:11436944 PMID:15060759 NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions ISO [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Timolol binds to and results in decreased activity of ADRB2 protein CTD PMID:11436944 PMID:17925438 NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512 		JBrowse link
G Aoc1 amine oxidase, copper containing 1 multiple interactions EXP Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein] CTD PMID:2860926 NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects response to substance ISO CYP2D6 gene SNP affects the susceptibility to Timolol CTD PMID:19284319 PMID:20925579 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO
EXP		 [Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]		 CTD PMID:11914123 PMID:18977218 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO
EXP		 [Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]		 CTD PMID:11914123 PMID:18977218 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Rgs3 regulator of G-protein signaling 3 multiple interactions ISO RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894 		JBrowse link
G Rgs4 regulator of G-protein signaling 4 multiple interactions ISO RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068 		JBrowse link
2,6-dimethyl-4-tridecylmorpholine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 affects expression ISO tridemorph affects the expression of CYP26A1 mRNA CTD PMID:34737147 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204 		JBrowse link
G Gata4 GATA binding protein 4 increases expression ISO tridemorph results in increased expression of GATA4 mRNA CTD PMID:34737147 NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636 		JBrowse link
G Msmo1 methylsterol monooxygenase 1 increases expression ISO tridemorph results in increased expression of MSMO1 mRNA CTD PMID:34737147 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016 		JBrowse link
G Myh14 myosin heavy chain 14 decreases expression ISO tridemorph results in decreased expression of MYH14 protein CTD PMID:34737147 NCBI chr 1:95,096,266...95,158,861
Ensembl chr 1:95,096,266...95,158,836 		JBrowse link
G Myh6 myosin heavy chain 6 decreases expression ISO tridemorph results in decreased expression of MYH6 mRNA CTD PMID:34737147 NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720 		JBrowse link
G Nes nestin increases expression ISO tridemorph results in increased expression of NES mRNA CTD PMID:34737147 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nkx2-5 NK2 homeobox 5 decreases expression ISO tridemorph results in decreased expression of NKX2-5 mRNA CTD PMID:34737147 NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO tridemorph results in increased expression of POU5F1 mRNA CTD PMID:34737147 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Top1 DNA topoisomerase I increases activity ISO 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin results in increased activity of TOP1 protein CTD PMID:2164630 NCBI chr 3:149,293,658...149,375,405
Ensembl chr 3:149,293,403...149,376,623 		JBrowse link
4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 increases expression ISO fenpropimorph results in increased expression of ALDH1A2 mRNA CTD PMID:34737147 NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107 		JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO fenpropimorph results in increased expression of CYP26A1 mRNA CTD PMID:34737147 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204 		JBrowse link
G Cyp51 cytochrome P450, family 51 increases expression ISO fenpropimorph results in increased expression of CYP51 mRNA CTD PMID:34737147 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 		JBrowse link
G Msmo1 methylsterol monooxygenase 1 increases expression ISO fenpropimorph results in increased expression of MSMO1 mRNA CTD PMID:34737147 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016 		JBrowse link
G Myh14 myosin heavy chain 14 decreases expression ISO fenpropimorph results in decreased expression of MYH14 protein CTD PMID:34737147 NCBI chr 1:95,096,266...95,158,861
Ensembl chr 1:95,096,266...95,158,836 		JBrowse link
G Myh6 myosin heavy chain 6 decreases expression ISO fenpropimorph results in decreased expression of MYH6 mRNA CTD PMID:34737147 NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720 		JBrowse link
G Nes nestin increases expression ISO fenpropimorph results in increased expression of NES mRNA CTD PMID:34737147 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nkx2-5 NK2 homeobox 5 decreases expression ISO fenpropimorph results in decreased expression of NKX2-5 mRNA CTD PMID:34737147 NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934 		JBrowse link
G Tfap2a transcription factor AP-2 alpha increases expression ISO fenpropimorph results in increased expression of TFAP2A protein CTD PMID:34737147 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tubb3 tubulin, beta 3 class III increases expression ISO fenpropimorph results in increased expression of TUBB3 mRNA CTD PMID:34737147 NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243 		JBrowse link
AH23848 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein CTD PMID:19407222 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Arrb1 arrestin, beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein CTD PMID:19407222 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061 		JBrowse link
G Axin1 axin 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein] CTD PMID:19407222 NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein CTD PMID:19407222 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein CTD PMID:19407222 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein CTD PMID:19407222 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein CTD PMID:19407222 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein
AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]		 CTD PMID:19407222 PMID:32115946 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein CTD PMID:19407222 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] CTD PMID:20678559 PMID:28571770 NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 multiple interactions ISO AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] CTD PMID:20093341 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein CTD PMID:19407222 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Egr1 early growth response 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of EGR1 protein CTD PMID:19407222 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of FOS protein CTD PMID:19407222 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein CTD PMID:19407222 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein CTD PMID:19407222 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of JUN protein CTD PMID:19407222 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Lep leptin multiple interactions ISO AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] CTD PMID:28571770 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein CTD PMID:19407222 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein CTD PMID:19407222 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MYC protein CTD PMID:19407222 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of NFKB1 protein CTD PMID:19407222 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of NFKBIA protein CTD PMID:19407222 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein CTD PMID:19407222 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Ptger2 prostaglandin E receptor 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein] CTD PMID:19407222 NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714 		JBrowse link
G Ptger4 prostaglandin E receptor 4 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein] CTD PMID:19407222 NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] CTD PMID:20678559 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein CTD PMID:19407222 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of SP1 protein CTD PMID:19407222 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein CTD PMID:19407222 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Tcf7 transcription factor 7 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7 protein CTD PMID:19407222 NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535 		JBrowse link
G Tcf7l2 transcription factor 7 like 2 multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7L2 protein CTD PMID:19407222 NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] CTD PMID:9298541 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein CTD PMID:19407222 NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591 		JBrowse link
alectinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alk ALK receptor tyrosine kinase affects response to substance
decreases activity		 ISO ALK protein affects the susceptibility to alectinib
alectinib results in decreased activity of ALK protein		 CTD PMID:26144315 PMID:29458018 NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO alectinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
amorolfine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] CTD PMID:23688403 NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO amorolfine inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; amorolfine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] CTD PMID:24471457 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] CTD PMID:23688403 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO amorolfine results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] CTD PMID:23688403 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO amorolfine inhibits the reaction [Biological Products results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:24471457 NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540 		JBrowse link
G Tslp thymic stromal lymphopoietin multiple interactions ISO 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] CTD PMID:23688403 NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548 		JBrowse link
aprepitant term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bad BCL2-associated agonist of cell death multiple interactions
increases expression		 ISO Arsenic Trioxide promotes the reaction [Aprepitant results in increased expression of BAD mRNA] CTD PMID:30145367 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression		 ISO Arsenic Trioxide promotes the reaction [Aprepitant results in increased expression of BAX mRNA] CTD PMID:30145367 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of BCL2 mRNA CTD PMID:30145367 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of BID mRNA CTD PMID:30145367 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions		 ISO Aprepitant results in decreased expression of BIRC2 mRNA
Arsenic Trioxide promotes the reaction [Aprepitant results in decreased expression of BIRC2 mRNA]		 CTD PMID:30145367 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions
decreases expression		 ISO Arsenic Trioxide promotes the reaction [Aprepitant results in decreased expression of BIRC3 mRNA] CTD PMID:30145367 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of BIRC5 mRNA CTD PMID:30145367 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions		 ISO Aprepitant results in increased activity of CASP3 protein
Aprepitant promotes the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; Arsenic Trioxide promotes the reaction [Aprepitant results in increased activity of CASP3 protein]		 CTD PMID:30145367 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of CDKN1A mRNA CTD PMID:30145367 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of MCL1 mRNA CTD PMID:30145367 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mmp12 matrix metallopeptidase 12 multiple interactions ISO aprepitant inhibits the reaction [TAC1 protein results in increased expression of MMP12 mRNA] CTD PMID:18441096 NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of MYC mRNA CTD PMID:30145367 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nfkbia NFKB inhibitor alpha decreases phosphorylation
multiple interactions		 ISO Aprepitant results in decreased phosphorylation of NFKBIA protein
Arsenic Trioxide promotes the reaction [Aprepitant results in decreased phosphorylation of NFKBIA protein]		 CTD PMID:30145367 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Pgr progesterone receptor multiple interactions ISO aprepitant binds to and results in decreased activity of PGR protein CTD PMID:25752796 NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344 		JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions ISO aprepitant inhibits the reaction [TAC1 protein results in increased expression of MMP12 mRNA]; aprepitant inhibits the reaction [TAC1 protein results in increased expression of TACR1 mRNA] CTD PMID:18441096 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178 		JBrowse link
G Tacr1 tachykinin receptor 1 multiple interactions ISO aprepitant binds to and results in decreased activity of TACR1 protein
aprepitant inhibits the reaction [TAC1 protein results in increased expression of TACR1 mRNA]		 CTD PMID:18441096 PMID:20623144 PMID:20718754 NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733 		JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO aprepitant binds to and results in decreased activity of THRA protein CTD PMID:25752796 NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936 		JBrowse link
G Tp73 tumor protein p73 multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in increased expression of TP73 mRNA CTD PMID:30145367 NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [Arsenic Trioxide co-treated with Aprepitant] results in decreased expression of XIAP mRNA CTD PMID:30145367 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700 		JBrowse link
BKM120 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccne1 cyclin E1 decreases expression EXP BKM120 decreases expression of cyclin E protein in rat pituitary tumor cell line RGD PMID:26983879 RGD:152177690 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Prl prolactin decreases expression EXP BKM120 decreases expression of prolactin protein in serum of treated rats RGD PMID:26983879 RGD:152177690 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062 		JBrowse link
canertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of AIFM1 protein] CTD PMID:28123000 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CCND1 protein] CTD PMID:28123000 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CDK4 protein] CTD PMID:28123000 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases phosphorylation
decreases activity		 ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]
Canertinib results in decreased phosphorylation of EGFR protein
Canertinib results in decreased activity of EGFR protein; Canertinib results in decreased activity of EGFR protein mutant form		 CTD PMID:15956251 PMID:18927496 PMID:21322567 PMID:28123000 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Endog endonuclease G multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of ENDOG protein] CTD PMID:28123000 NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] CTD PMID:18927496 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] CTD PMID:18927496 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of RB1 protein] CTD PMID:28123000 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO Canertinib results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
decreases secretion		 ISO Canertinib results in decreased expression of VEGFA mRNA; Canertinib results in decreased expression of VEGFA protein
Canertinib results in decreased secretion of VEGFA protein		 CTD PMID:15956251 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
carfilzomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Afp alpha-fetoprotein multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:24632418 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480 		JBrowse link
G Ar androgen receptor multiple interactions ISO carfilzomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:30818834 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Brca1 BRCA1, DNA repair associated increases response to substance ISO BRCA1 mutant form results in increased susceptibility to carfilzomib CTD PMID:25522274 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304 		JBrowse link
G Brd4 bromodomain containing 4 multiple interactions ISO carfilzomib inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein] CTD PMID:26051217 NCBI chr 7:11,216,446...11,296,029
Ensembl chr 7:11,216,446...11,295,539 		JBrowse link
G Bsg basigin (Ok blood group) multiple interactions
decreases expression		 ISO carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]
carfilzomib results in decreased expression of BSG mRNA		 CTD PMID:27769052 NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387 		JBrowse link
G Casp3 caspase 3 increases cleavage ISO carfilzomib results in increased cleavage of CASP3 protein CTD PMID:27769052 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO carfilzomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression
multiple interactions		 ISO carfilzomib results in decreased expression of CXCR4 mRNA
carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA]		 CTD PMID:27769052 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:30818834 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO carfilzomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:30818834 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Esrra estrogen related receptor, alpha multiple interactions ISO carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; carfilzomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] CTD PMID:30818834 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased activity of GPT protein] CTD PMID:27900802 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:24632418 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases activity ISO carfilzomib results in increased activity of NFE2L2 protein CTD PMID:30818834 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA] CTD PMID:27900802 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Pgr progesterone receptor multiple interactions ISO carfilzomib inhibits the reaction [Promegestone results in increased activity of PGR protein] CTD PMID:30818834 NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO carfilzomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] CTD PMID:30818834 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Prkcsh protein kinase C substrate 80K-H increases response to substance ISO PRKCSH gene mutant form results in increased susceptibility to carfilzomib CTD PMID:21685914 NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of PTGS2 mRNA] CTD PMID:27900802 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO carfilzomib results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions EXP carfilzomib inhibits the reaction [Diethylnitrosamine results in increased expression of TIMP1 protein] CTD PMID:24632418 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO carfilzomib inhibits the reaction [Acetaminophen results in increased expression of TNF protein] CTD PMID:27900802 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tp53 tumor protein p53 increases activity
affects activity		 ISO carfilzomib results in increased activity of TP53 protein
carfilzomib affects the activity of TP53 protein		 CTD PMID:30818834 PMID:35435491 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Zfand2a zinc finger AN1-type containing 2A increases expression ISO carfilzomib results in increased expression of ZFAND2A protein CTD PMID:31540997 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677 		JBrowse link
cobicistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf3 activating transcription factor 3 multiple interactions ISO [Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA CTD PMID:33629115 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA CTD PMID:33629115 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Cbr3 carbonyl reductase 3 multiple interactions ISO [Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA CTD PMID:33629115 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions ISO [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat CTD PMID:33629115 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA CTD PMID:33629115 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA CTD PMID:33629115 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Cobicistat] results in increased expression of HSPA5 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA CTD PMID:33629115 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ngfr nerve growth factor receptor multiple interactions ISO [Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA CTD PMID:33629115 NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat CTD PMID:33629115 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased susceptibility to Cobicistat CTD PMID:33629115 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
copanlisib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO copanlisib results in decreased phosphorylation of AKT1 protein CTD PMID:31445927 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Fas Fas cell surface death receptor affects response to substance ISO copanlisib affects the susceptibility to FAS protein CTD PMID:31445927 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Tnf tumor necrosis factor increases response to substance ISO copanlisib results in increased susceptibility to TNF protein CTD PMID:31445927 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
dimethomorph term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Amh anti-Mullerian hormone decreases expression EXP dimethomorph results in decreased expression of AMH mRNA CTD PMID:36410587 NCBI chr 7:8,906,776...8,909,184
Ensembl chr 7:8,906,836...8,909,282 		JBrowse link
G Anxa10 annexin A10 increases expression ISO dimethomorph results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648 		JBrowse link
G Ar androgen receptor multiple interactions ISO dimethomorph inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; dimethomorph inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 PMID:33049310 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Arg1 arginase 1 decreases expression ISO dimethomorph results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP dimethomorph results in increased expression of BAX mRNA CTD PMID:36410587 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bmp15 bone morphogenetic protein 15 increases expression EXP dimethomorph results in increased expression of BMP15 mRNA CTD PMID:36410587 NCBI chr  X:16,169,123...16,174,187
Ensembl chr  X:16,169,123...16,174,187 		JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases expression ISO dimethomorph results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression ISO dimethomorph results in decreased expression of CYP7A1 mRNA; dimethomorph results in decreased expression of CYP7A1 protein CTD PMID:32194361 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688 		JBrowse link
G Ddx4 DEAD-box helicase 4 increases expression EXP dimethomorph results in increased expression of DDX4 mRNA CTD PMID:36410587 NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO dimethomorph binds to and results in increased activity of ESR1 protein CTD PMID:33049310 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO dimethomorph results in decreased expression of G6PC1 mRNA CTD PMID:32194361 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 decreases expression EXP dimethomorph results in decreased expression of HSD3B1 mRNA CTD PMID:36410587 NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999 		JBrowse link
G Inha inhibin subunit alpha decreases expression EXP dimethomorph results in decreased expression of INHA mRNA CTD PMID:36410587 NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO dimethomorph binds to and results in increased activity of NR1I2 protein CTD PMID:33049310 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Pcna proliferating cell nuclear antigen increases expression EXP dimethomorph results in increased expression of PCNA mRNA CTD PMID:36410587 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pde4a phosphodiesterase 4A decreases activity ISO dimethomorph results in decreased activity of PDE4A protein CTD PMID:21251949 NCBI chr 8:19,706,649...19,751,937
Ensembl chr 8:19,703,290...19,751,961 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO dimethomorph binds to and results in increased activity of PPARG protein CTD PMID:33049310 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Star steroidogenic acute regulatory protein decreases expression EXP dimethomorph results in decreased expression of STAR mRNA CTD PMID:36410587 NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672 		JBrowse link
doramapimod term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO doramapimod results in increased expression of ABCC2 mRNA CTD PMID:21328587 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Actg2 actin gamma 2, smooth muscle increases expression EXP doramapimod results in increased expression of ACTG2 mRNA CTD PMID:24303162 NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465 		JBrowse link
G Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide increases expression EXP doramapimod results in increased expression of ADH7 mRNA CTD PMID:24303162 NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182 		JBrowse link
G Ahsg alpha-2-HS-glycoprotein decreases expression ISO doramapimod results in decreased expression of AHSG mRNA CTD PMID:21328587 NCBI chr11:78,117,903...78,145,956
Ensembl chr11:78,117,918...78,145,999 		JBrowse link
G Ak5 adenylate kinase 5 increases expression EXP doramapimod results in increased expression of AK5 mRNA CTD PMID:24303162 NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458 		JBrowse link
G Akr1b7 aldo-keto reductase family 1, member B7 increases expression ISO doramapimod results in increased expression of AKR1B7 mRNA CTD PMID:21328587 NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502 		JBrowse link
G Apoa4 apolipoprotein A4 decreases expression ISO doramapimod results in decreased expression of APOA4 mRNA CTD PMID:21328587 NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469 		JBrowse link
G C1qa complement C1q A chain decreases expression ISO doramapimod results in decreased expression of C1QA mRNA CTD PMID:21328587 NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534 		JBrowse link
G C1qb complement C1q B chain decreases expression ISO doramapimod results in decreased expression of C1QB mRNA CTD PMID:21328587 NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407 		JBrowse link
G Car3 carbonic anhydrase 3 decreases expression ISO doramapimod results in decreased expression of CAR3 mRNA CTD PMID:21328587 NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO doramapimod promotes the reaction [TNF protein results in increased activity of CASP3 protein] CTD PMID:28629242 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cd5l Cd5 molecule-like decreases expression ISO doramapimod results in decreased expression of CD5L mRNA CTD PMID:21328587 NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753 		JBrowse link
G Cd74 CD74 molecule decreases expression ISO doramapimod results in decreased expression of CD74 mRNA CTD PMID:21328587 NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003 		JBrowse link
G Ceacam1 CEA cell adhesion molecule 1 decreases expression EXP doramapimod results in decreased expression of CEACAM1 mRNA CTD PMID:24303162 NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992 		JBrowse link
G Ces3a carboxylesterase 3a increases expression ISO doramapimod results in increased expression of CES3 mRNA CTD PMID:21328587 NCBI chr19:32,992,386...33,000,562 JBrowse link
G Clec1b C-type lectin domain family 1, member B decreases expression ISO doramapimod results in decreased expression of CLEC1B mRNA CTD PMID:21328587 NCBI chr 4:162,847,978...162,856,291
Ensembl chr 4:162,848,010...162,856,291 		JBrowse link
G Ctss cathepsin S decreases expression ISO doramapimod results in decreased expression of CTSS mRNA CTD PMID:21328587 NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases secretion ISO doramapimod results in decreased secretion of CXCL10 protein CTD PMID:17996064 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL1 protein] CTD PMID:14997032 NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cxcr1 C-X-C motif chemokine receptor 1 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR1 protein] CTD PMID:14997032 NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084 		JBrowse link
G Cxcr2 C-X-C motif chemokine receptor 2 multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR2 protein] CTD PMID:14997032 NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression ISO doramapimod results in increased expression of CYP2A4 mRNA CTD PMID:21328587 NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979 		JBrowse link
G Cyss cystatin S decreases expression EXP doramapimod results in decreased expression of CYSS mRNA CTD PMID:24303162 NCBI chr 3:137,432,272...137,436,610
Ensembl chr 3:137,432,049...137,436,610 		JBrowse link
G Egr1 early growth response 1 increases expression ISO doramapimod results in increased expression of EGR1 mRNA CTD PMID:21328587 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Fcgr2b Fc gamma receptor 2B decreases expression ISO doramapimod results in decreased expression of FCGR2B mRNA CTD PMID:21328587 NCBI chr13:83,191,253...83,207,776
Ensembl chr13:83,193,163...83,207,778 		JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression EXP doramapimod results in decreased expression of FGF8 mRNA CTD PMID:24303162 NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO doramapimod results in decreased expression of G6PC mRNA CTD PMID:21328587 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression ISO doramapimod results in increased expression of GCLC mRNA CTD PMID:21328587 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gpx2 glutathione peroxidase 2 increases expression ISO doramapimod results in increased expression of GPX2 mRNA CTD PMID:21328587 NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877 		JBrowse link
G Grm8 glutamate metabotropic receptor 8 increases expression EXP doramapimod results in increased expression of GRM8 mRNA CTD PMID:24303162 NCBI chr 4:55,805,762...56,731,690
Ensembl chr 4:55,805,955...56,730,831 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression ISO doramapimod results in increased expression of GSTA1 mRNA CTD PMID:21328587 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798 		JBrowse link
G Gstm2 glutathione S-transferase mu 2 increases expression ISO doramapimod results in increased expression of GSTM2 mRNA CTD PMID:21328587 NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961 		JBrowse link
G Gstm5 glutathione S-transferase, mu 5 increases expression ISO doramapimod results in increased expression of GSTM3 mRNA CTD PMID:21328587 NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553 		JBrowse link
G Hp haptoglobin decreases expression ISO doramapimod results in decreased expression of HP mRNA CTD PMID:21328587 NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523 		JBrowse link
G Hpd 4-hydroxyphenylpyruvate dioxygenase decreases expression EXP doramapimod results in decreased expression of HPD mRNA CTD PMID:24303162 NCBI chr12:33,381,397...33,392,750
Ensembl chr12:33,381,231...33,392,766 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO doramapimod inhibits the reaction [Dinitrofluorobenzene results in increased expression of ICAM1 protein] CTD PMID:19427879 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] CTD PMID:28629242 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 decreases expression EXP doramapimod results in decreased expression of KCNK1 mRNA CTD PMID:24303162 NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724 		JBrowse link
G Lmod1 leiomodin 1 increases expression EXP doramapimod results in increased expression of LMOD1 mRNA CTD PMID:24303162 NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases activity ISO doramapimod results in decreased activity of MAPK14 protein CTD PMID:28629242 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589 		JBrowse link
G Meig1 meiosis/spermiogenesis associated 1 increases expression ISO doramapimod results in increased expression of MEIG1 mRNA CTD PMID:21328587 NCBI chr17:74,810,791...74,828,433
Ensembl chr17:74,814,632...74,828,433 		JBrowse link
G Mybpc1 myosin binding protein C1 decreases expression EXP doramapimod results in decreased expression of MYBPC1 mRNA CTD PMID:24303162 NCBI chr 7:22,930,350...23,015,981
Ensembl chr 7:22,930,350...23,015,957 		JBrowse link
G Myh11 myosin heavy chain 11 increases expression EXP doramapimod results in increased expression of MYH11 mRNA CTD PMID:24303162 NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459 		JBrowse link
G Myh3 myosin heavy chain 3 increases expression EXP doramapimod results in increased expression of MYH3 mRNA CTD PMID:24303162 NCBI chr10:51,770,177...51,793,994
Ensembl chr10:51,770,177...51,793,992 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO doramapimod results in increased expression of NQO1 mRNA CTD PMID:21328587 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Olr59 olfactory receptor 59 increases expression EXP doramapimod results in increased expression of OLR59 mRNA CTD PMID:24303162 NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179 		JBrowse link
G Otog otogelin decreases expression EXP doramapimod results in decreased expression of OTOG mRNA CTD PMID:24303162 NCBI chr 1:96,746,336...96,815,416
Ensembl chr 1:96,746,336...96,815,415 		JBrowse link
G Pfn2 profilin 2 increases expression ISO doramapimod results in increased expression of PFN2 mRNA CTD PMID:21328587 NCBI chr 2:142,067,102...142,072,938
Ensembl chr 2:142,067,104...142,072,938 		JBrowse link
G Pon1 paraoxonase 1 decreases expression EXP doramapimod results in decreased expression of PON1 mRNA CTD PMID:24303162 NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression ISO doramapimod results in increased expression of PPARG mRNA CTD PMID:21328587 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Prm2 protamine 2 increases expression ISO doramapimod results in increased expression of PRM2 mRNA CTD PMID:21328587 NCBI chr10:4,876,398...4,876,834
Ensembl chr10:4,873,372...4,877,026 		JBrowse link
G Rgs4 regulator of G-protein signaling 4 increases expression EXP doramapimod results in increased expression of RGS4 mRNA CTD PMID:24303162 NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068 		JBrowse link
G RT1-Bb RT1 class II, locus Bb decreases expression ISO doramapimod results in decreased expression of H2-AB1 mRNA CTD PMID:21328587 NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression ISO doramapimod results in increased expression of SLC7A11 mRNA CTD PMID:21328587 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Spock2 SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2 decreases expression EXP doramapimod results in decreased expression of SPOCK2 mRNA CTD PMID:24303162 NCBI chr20:28,036,909...28,064,272
Ensembl chr20:28,033,475...28,064,272 		JBrowse link
G Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 decreases expression ISO doramapimod results in decreased expression of SPSB1 mRNA CTD PMID:21328587 NCBI chr 5:160,358,292...160,418,541
Ensembl chr 5:160,358,308...160,418,468 		JBrowse link
G Srxn1 sulfiredoxin 1 increases expression ISO doramapimod results in increased expression of SRXN1 mRNA CTD PMID:21328587 NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448 		JBrowse link
G Stmn2 stathmin 2 increases expression EXP doramapimod results in increased expression of STMN2 mRNA CTD PMID:24303162 NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO doramapimod inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; doramapimod promotes the reaction [TNF protein results in increased activity of CASP3 protein] CTD PMID:28629242 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vsig4 V-set and immunoglobulin domain containing 4 decreases expression ISO doramapimod results in decreased expression of VSIG4 mRNA CTD PMID:21328587 NCBI chr  X:61,144,926...61,170,212
Ensembl chr  X:61,144,928...61,170,212 		JBrowse link
doxapram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crh corticotropin releasing hormone increases expression EXP Doxapram results in increased expression of CRH mRNA; Doxapram results in increased expression of CRH protein CTD PMID:16269353 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919 		JBrowse link
G Prl prolactin increases expression ISO Doxapram results in increased expression of PRL protein CTD PMID:15741000 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062 		JBrowse link
epoxomicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions
affects localization		 ISO epoxomicin inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]
epoxomicin affects the localization of AHR protein		 CTD PMID:17445780 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ATF4 protein]] CTD PMID:25639565 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of BAX protein]] CTD PMID:25639565 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of BCL2 protein]] CTD PMID:25639565 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
multiple interactions		 ISO epoxomicin results in increased expression of BIRC5 protein
epoxomicin inhibits the reaction [Aspirin results in decreased expression of BIRC5 protein]		 CTD PMID:17510429 PMID:18483385 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:25639565 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions		 ISO epoxomicin results in increased expression of CDH1 protein
NFE2L2 protein alternative form inhibits the reaction [epoxomicin results in increased expression of CDH1 protein]		 CTD PMID:35124418 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO epoxomicin inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO epoxomicin affects the expression of CFLAR protein alternative form CTD PMID:17510429 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Dao D-amino-acid oxidase affects localization ISO epoxomicin affects the localization of DAO protein CTD PMID:28451739 NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2AK3 protein]] CTD PMID:25639565 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2S1 protein]] CTD PMID:25639565 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ERN1 protein]] CTD PMID:25639565 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression		 ISO epoxomicin inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; epoxomicin inhibits the reaction [scutellarin results in decreased expression of HIF1A protein]
epoxomicin results in increased expression of HIF1A protein		 CTD PMID:25192544 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hsf1 heat shock transcription factor 1 increases activity ISO epoxomicin results in increased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011 		JBrowse link
G Nfe2l1 NFE2 like bZIP transcription factor 1 multiple interactions
increases expression		 ISO epoxomicin results in increased expression of and affects the localization of NFE2L1 protein; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMA2 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMC4 mRNA]
epoxomicin results in increased expression of NFE2L1 protein alternative form
NFE2L1 alternative form affects the reaction [epoxomicin results in increased expression of NFE2L1 protein alternative form]		 CTD PMID:27345029 PMID:32980394 NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions		 ISO epoxomicin results in increased expression of NFE2L2 protein
NFE2L2 protein alternative form inhibits the reaction [epoxomicin results in increased expression of CDH1 protein]		 CTD PMID:22558124 PMID:35124418 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Optn optineurin increases expression ISO
EXP		 epoxomicin results in increased expression of OPTN protein CTD PMID:21059646 NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251 		JBrowse link
G Pacrg parkin coregulated decreases expression EXP
ISO		 epoxomicin results in decreased expression of PACRG mRNA CTD PMID:18586549 NCBI chr 1:49,882,671...50,305,564
Ensembl chr 1:49,882,630...50,305,430 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [epoxomicin results in increased cleavage of PARP1 protein] CTD PMID:20153345 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdyn prodynorphin multiple interactions
decreases expression		 ISO
EXP		 epoxomicin inhibits the reaction [Potassium results in increased secretion of PDYN protein alternative form]; epoxomicin results in decreased expression of and results in decreased secretion of PDYN protein alternative form
epoxomicin results in decreased expression of PDYN protein alternative form		 CTD PMID:17670969 NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO epoxomicin inhibits the reaction [resveratrol results in decreased expression of PPARG protein]; epoxomicin inhibits the reaction [rosiglitazone results in decreased expression of PPARG protein] CTD PMID:18555852 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases expression
multiple interactions		 ISO
EXP		 epoxomicin results in decreased expression of PRKN mRNA
epoxomicin inhibits the reaction [PRKN protein results in decreased susceptibility to Ceramides]		 CTD PMID:12588799 PMID:18586549 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Psma2 proteasome 20S subunit alpha 2 multiple interactions
increases expression		 ISO NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMA2 mRNA] CTD PMID:27345029 NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938 		JBrowse link
G Psmb6 proteasome 20S subunit beta 6 increases expression
multiple interactions		 ISO epoxomicin results in increased expression of PSMB6 mRNA
Ascorbic Acid inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; sulforaphane inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]		 CTD PMID:27345029 NCBI chr10:55,239,274...55,241,581
Ensembl chr10:55,239,241...55,241,586 		JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 multiple interactions
increases expression		 ISO NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMC4 mRNA] CTD PMID:27345029 NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions
increases ubiquitination		 ISO epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of SP1 protein]; epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in increased degradation of SP1 protein]
epoxomicin results in increased ubiquitination of SP1 protein		 CTD PMID:17409431 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Taf1 TATA-box binding protein associated factor 1 multiple interactions ISO epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of TAF1 protein] CTD PMID:17409431 NCBI chr  X:66,640,915...66,716,543
Ensembl chr  X:66,640,982...66,716,543 		JBrowse link
G Tardbp TAR DNA binding protein multiple interactions ISO epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein] CTD PMID:24477737 NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055 		JBrowse link
gefitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO gefitinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin] CTD PMID:17938326 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
decreases expression		 ISO [Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein
Gefitinib results in decreased expression of ACTA2 protein		 CTD PMID:33248157 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO gefitinib results in decreased expression of ADORA1 mRNA CTD PMID:16685379 NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]		 CTD PMID:17805209 PMID:19233551 PMID:23255615 PMID:23948867 PMID:24568969 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ar androgen receptor multiple interactions ISO Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] CTD PMID:29383186 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Areg amphiregulin affects response to substance
multiple interactions
decreases response to substance		 ISO AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib		 CTD PMID:15496427 PMID:15723263 PMID:16230376 PMID:18980991 PMID:21258428 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535 		JBrowse link
G Atg5 autophagy related 5 increases expression ISO gefitinib results in increased expression of ATG5 protein CTD PMID:21655094 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 increases expression ISO gefitinib results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Aurka aurora kinase A decreases response to substance
multiple interactions		 ISO AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib		 CTD PMID:21216229 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390 		JBrowse link
G Aven apoptosis and caspase activation inhibitor affects response to substance ISO AVEN protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein CTD PMID:32370496 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2l11 Bcl2-like 11 increases response to substance ISO BCL2L11 protein results in increased susceptibility to gefitinib CTD PMID:20237869 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
decreases expression
multiple interactions		 ISO gefitinib results in increased expression of BIRC5 protein
gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]		 CTD PMID:17473213 PMID:28942004 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp1 caspase 1 increases activity
multiple interactions		 ISO Gefitinib metabolite results in increased activity of CASP1 protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Gefitinib metabolite results in increased activity of CASP1 protein]		 CTD PMID:33132241 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
Gefitinib results in increased expression of CASP3 protein modified form
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]
EGFR gene mutant form promotes the reaction [gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; gefitinib results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:23523951 PMID:27084042 PMID:27639429 PMID:33248157 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases cleavage ISO Gefitinib results in increased cleavage of CASP8 protein CTD PMID:31168030 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Cav1 caveolin 1 increases expression ISO gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein CTD PMID:19288272 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
increases expression
multiple interactions		 ISO Gefitinib results in increased secretion of CCL2 protein
Gefitinib results in increased expression of CCL2 mRNA
[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]		 CTD PMID:33248157 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO Gefitinib results in decreased expression of and affects the localization of CCNB1 protein CTD PMID:33548356 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO gefitinib results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]		 CTD PMID:16740687 PMID:17513607 PMID:23948867 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO gefitinib results in decreased expression of CCND3 protein CTD PMID:16740687 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Cd14 CD14 molecule multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]] CTD PMID:20226526 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression		 ISO [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein
Gefitinib results in increased expression of CDH1 protein		 CTD PMID:33248157 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases phosphorylation ISO Gefitinib results in increased phosphorylation of CDK1 protein CTD PMID:33548356 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression		 ISO Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
decreases expression		 ISO gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]		 CTD PMID:17513607 PMID:28942004 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
decreases expression		 ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B		 CTD PMID:14679152 PMID:16322342 PMID:16740687 PMID:17513607 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050 		JBrowse link
G Cert1 ceramide transporter 1 affects response to substance ISO CERT1 protein affects the susceptibility to Gefitinib CTD PMID:15496427 NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074 		JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 increases expression ISO gefitinib results in increased expression of CGRRF1 mRNA CTD PMID:16685379 NCBI chr15:20,088,564...20,109,042
Ensembl chr15:20,088,571...20,109,037 		JBrowse link
G Cldn2 claudin 2 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA CTD PMID:20935109 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of COL1A1 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein		 CTD PMID:33248157 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Coro1c coronin 1C affects response to substance ISO CORO1C protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr12:42,712,960...42,785,179
Ensembl chr12:42,712,991...42,785,179 		JBrowse link
G Cycs cytochrome c, somatic affects localization ISO gefitinib affects the localization of CYCS protein CTD PMID:23523951 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases response to substance
decreases activity
increases expression		 ISO
EXP		 CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in decreased activity of CYP1A1 protein
Gefitinib results in increased expression of CYP1A1 mRNA		 CTD PMID:28652202 PMID:32370496 PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Gefitinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Gefitinib; CYP2D6 protein polymorphism affects the metabolism of Gefitinib CTD PMID:15788367 PMID:34936353 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO gefitinib results in decreased expression of CYP2F1 mRNA CTD PMID:16685379 NCBI chr 1:82,416,108...82,429,897
Ensembl chr 1:82,416,130...82,429,896 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Gefitinib CTD PMID:15788367 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases secretion ISO Gefitinib metabolite results in increased secretion of DNAJB1 protein CTD PMID:33132241 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dusp3 dual specificity phosphatase 3 affects response to substance ISO DUSP3 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962 		JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO gefitinib results in decreased expression of DUSP9 mRNA CTD PMID:16685379 NCBI chr  X:151,351,897...151,355,822
Ensembl chr  X:151,351,897...151,355,821 		JBrowse link
G E2f1 E2F transcription factor 1 decreases expression ISO gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein CTD PMID:17094457 PMID:18347146 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA] CTD PMID:18424623 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]		 CTD PMID:15841081 PMID:16243822 PMID:17805209 PMID:17898861 PMID:18927496 More... NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance		 ISO
EXP		 EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
gefitinib results in decreased activity of EGFR protein
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib		 CTD PMID:13680161 PMID:14679152 PMID:15660382 PMID:15723263 PMID:15841081 More... NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Epor erythropoietin receptor increases expression ISO gefitinib results in increased expression of EPOR mRNA CTD PMID:16685379 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257 		JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO gefitinib results in increased expression of EPS15 mRNA CTD PMID:16685379 NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein		 CTD PMID:16243822 PMID:17898861 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
affects response to substance		 ISO ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib		 CTD PMID:21264830 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963 		JBrowse link
G Esr1 estrogen receptor 1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of ESR1 protein CTD PMID:16261397 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 increases expression
multiple interactions		 ISO gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]		 CTD PMID:20005069 PMID:29383186 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Faslg Fas ligand multiple interactions
increases response to substance		 ISO benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein] CTD PMID:31168030 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fgf6 fibroblast growth factor 6 increases expression ISO gefitinib results in increased expression of FGF6 mRNA CTD PMID:16685379 NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein CTD PMID:33248157 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Foxf1 forkhead box F1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA] CTD PMID:18424623 NCBI chr19:49,153,729...49,157,741
Ensembl chr19:49,153,699...49,157,738 		JBrowse link
G Foxo3 forkhead box O3 increases response to substance
increases expression
multiple interactions		 ISO
EXP		 FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein		 CTD PMID:18089711 PMID:32370496 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO gefitinib results in increased expression of GADD45A mRNA CTD PMID:16685379 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression ISO gefitinib results in decreased expression of GADD45G mRNA CTD PMID:16685379 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 increases expression ISO Gefitinib results in increased expression of GARS1 mRNA CTD PMID:16685379 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects response to substance ISO GCLC protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]] CTD PMID:29228391 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gnb2 G protein subunit beta 2 decreases expression ISO gefitinib results in decreased expression of GNB2 mRNA CTD PMID:16685379 NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019 		JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA CTD PMID:20935109 NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Gefitinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Gefitinib results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gucy2d guanylate cyclase 2D, retinal decreases expression ISO gefitinib results in decreased expression of GUCY2D mRNA CTD PMID:16685379 NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein] CTD PMID:23255615 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO
EXP		 gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]		 CTD PMID:15723263 PMID:29228391 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein] CTD PMID:21544845 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgb1 high mobility group box 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HMGB1 protein CTD PMID:33132241 NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA		 CTD PMID:27084042 PMID:32741899 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HSP90AA1 protein CTD PMID:33132241 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases secretion ISO Gefitinib metabolite results in increased secretion of HSPA1A protein CTD PMID:33132241 NCBI chr20:3,870,765...3,873,221 JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases phosphorylation		 ISO gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein] CTD PMID:17473213 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein]
Gefitinib metabolite results in increased expression of IL1B protein		 CTD PMID:23948867 PMID:33132241 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein] CTD PMID:20226526 NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA] CTD PMID:15841081 NCBI chr 3:68,838,524...68,926,653
Ensembl chr 3:68,838,189...68,926,639 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib CTD PMID:21478906 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA] CTD PMID:18424623 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression ISO gefitinib results in increased expression of KEAP1 mRNA CTD PMID:27639429 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
decreases response to substance
multiple interactions		 ISO KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]		 CTD PMID:17270025 PMID:28739874 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein] CTD PMID:23255615 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095 		JBrowse link
G Lepr leptin receptor decreases expression ISO gefitinib results in decreased expression of LEPR mRNA CTD PMID:16685379 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908 		JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA CTD PMID:20935109 NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
decreases phosphorylation		 ISO gefitinib results in increased phosphorylation of MAPK8 protein
Gefitinib results in decreased phosphorylation of MAPK8 protein		 CTD PMID:20846305 PMID:35317323 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Marveld1 MARVEL domain containing 1 decreases response to substance ISO MARVELD1 protein results in decreased susceptibility to Gefitinib CTD PMID:27447558 NCBI chr 1:240,954,452...240,958,384
NCBI chr 1:240,953,889...240,958,096
Ensembl chr 1:240,954,452...240,958,384 		JBrowse link
G Mdk midkine multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA] CTD PMID:18424623 NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Gefitinib results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827 		JBrowse link
G Mill1 MHC I like leukocyte 1 increases expression ISO Gefitinib results in increased expression of MICA protein CTD PMID:21951556 NCBI chr 1:78,372,138...78,398,932
Ensembl chr 1:78,372,802...78,398,930 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein CTD PMID:27447558 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mlh1 mutL homolog 1 decreases expression ISO gefitinib results in decreased expression of MLH1 mRNA CTD PMID:16685379 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of MMP9 mRNA; Gefitinib results in decreased expression of MMP9 protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]		 CTD PMID:15841081 PMID:23127547 PMID:27087131 PMID:29228391 PMID:35317323 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mr1 major histocompatibility complex, class I-related affects expression ISO gefitinib affects the expression of MR1 mRNA CTD PMID:25811541 NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970 		JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA CTD PMID:32741899 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO gefitinib results in decreased phosphorylation of MTOR protein CTD PMID:21655094 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein] CTD PMID:21544845 NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Mug1 murinoglobulin 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA CTD PMID:20935109 NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO gefitinib results in decreased expression of MYC protein CTD PMID:17513607 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein CTD PMID:27084042 NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217 		JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA CTD PMID:20935109 NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression ISO gefitinib results in decreased expression of NFKB1 mRNA CTD PMID:16685379 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib CTD PMID:21216229 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nppa natriuretic peptide A increases expression
multiple interactions		 EXP Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]		 CTD PMID:32370496 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351 		JBrowse link
G Nppb natriuretic peptide B increases expression EXP gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein CTD PMID:27084042 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168 		JBrowse link
G Nptx2 neuronal pentraxin 2 decreases expression ISO gefitinib results in decreased expression of NPTX2 mRNA CTD PMID:16685379 NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345 		JBrowse link
G Nrl neural retina leucine zipper decreases expression ISO gefitinib results in decreased expression of NRL mRNA CTD PMID:16685379 NCBI chr15:29,008,104...29,009,832
Ensembl chr15:29,008,104...29,009,832 		JBrowse link
G Osmr oncostatin M receptor affects response to substance ISO OSMR protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage		 ISO Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]
gefitinib results in increased cleavage of PARP1 protein		 CTD PMID:16243822 PMID:23523951 PMID:30136359 PMID:33248157 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein] CTD PMID:23255615 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pcnt pericentrin decreases response to substance ISO PCNT protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr20:12,190,597...12,278,723
Ensembl chr20:12,191,648...12,278,710 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
decreases expression		 ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]
Gefitinib results in decreased expression of PECAM1 protein		 CTD PMID:18424623 PMID:35317323 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116 		JBrowse link
G Pgrmc1 progesterone receptor membrane component 1 decreases response to substance ISO PGRMC1 protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr  X:115,832,865...115,841,060
Ensembl chr  X:115,832,884...115,888,682 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 affects response to substance ISO PHLDA2 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plbd1 phospholipase B domain containing 1 affects response to substance ISO PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
increases expression		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form		 CTD PMID:32370496 NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]		 CTD PMID:16322342 PMID:23948867 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions
decreases response to substance		 ISO gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib		 CTD PMID:23523951 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837 		JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 increases expression ISO gefitinib results in increased expression of QSOX1 mRNA CTD PMID:16685379 NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459 		JBrowse link
G Rad51 RAD51 recombinase affects response to substance ISO RAD51 protein affects the susceptibility to Gefitinib CTD PMID:34998818 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression		 ISO Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form] CTD PMID:30136359 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rbm7 RNA binding motif protein 7 affects response to substance ISO RBM7 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:48,831,894...48,838,399
Ensembl chr 8:48,831,894...48,838,411 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases response to substance		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib		 CTD PMID:19318490 PMID:21216229 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rpa1 replication protein A1 increases expression ISO gefitinib results in increased expression of RPA1 mRNA CTD PMID:16685379 NCBI chr10:60,148,869...60,199,999
Ensembl chr10:60,148,793...60,199,949 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:21655094 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 affects response to substance ISO RRM1 gene polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261 		JBrowse link
G RT1-CE5 RT1 class I, locus CE5 affects expression ISO gefitinib affects the expression of HLA-F mRNA CTD PMID:25811541 NCBI chr20:3,403,418...3,479,476 JBrowse link
G RT1-Db1 RT1 class II, locus Db1 affects expression ISO gefitinib affects the expression of HLA-DRB1 mRNA CTD PMID:25811541 NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258 		JBrowse link
G RT1-DOa RT1 class II, locus DOa affects expression ISO gefitinib affects the expression of HLA-DOA mRNA CTD PMID:25811541 NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577 		JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA CTD PMID:20935109 NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180 		JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein CTD PMID:20935109 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643 		JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA] CTD PMID:18424623 NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646 		JBrowse link
G Sfn stratifin decreases expression ISO gefitinib results in decreased expression of SFN mRNA CTD PMID:16685379 Ensembl chr 5:145,826,201...145,831,314 JBrowse link
G Ski Ski proto-oncogene increases expression ISO gefitinib results in increased expression of SKI mRNA CTD PMID:16685379 NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733 		JBrowse link
G Slc10a3 solute carrier family 10, member 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA CTD PMID:20935109 NCBI chr  X:152,154,757...152,158,563
Ensembl chr  X:152,151,076...152,162,958 		JBrowse link
G Snai2 snail family transcriptional repressor 2 affects response to substance ISO SNAI2 protein affects the susceptibility to gefitinib CTD PMID:21037017 NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO gefitinib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression		 ISO [Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein] CTD PMID:25979647 PMID:27639429 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein CTD PMID:27447558 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]		 CTD PMID:19318490 PMID:21787763 PMID:23948867 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Synpo synaptopodin multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA CTD PMID:20935109 NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126 		JBrowse link
G Tek TEK receptor tyrosine kinase multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA] CTD PMID:18424623 NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804 		JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO gefitinib results in decreased expression of TERT mRNA CTD PMID:17094457 NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561 		JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 PMID:21951556 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tgfa transforming growth factor alpha decreases response to substance
multiple interactions		 ISO TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]		 CTD PMID:15723263 PMID:16230376 PMID:18424623 PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression		 ISO Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of TNF mRNA
Gefitinib results in decreased expression of and results in decreased secretion of TNF protein		 CTD PMID:15841081 PMID:23948867 PMID:35317323 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases expression ISO gefitinib results in decreased expression of TNFRSF1B mRNA CTD PMID:16685379 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206 		JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion EXP Gefitinib results in increased secretion of TNNI3 protein CTD PMID:32370496 NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
affects response to substance		 ISO
EXP		 [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib		 CTD PMID:21216229 PMID:27084042 PMID:29383186 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trim23 tripartite motif-containing 23 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA CTD PMID:20935109 NCBI chr 2:35,302,405...35,335,746
Ensembl chr 2:35,302,409...35,335,743 		JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA CTD PMID:20935109 NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 affects response to substance ISO TWIST1 protein affects the susceptibility to Gefitinib CTD PMID:30993382 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]		 CTD PMID:18347146 PMID:30136359 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
G Ulbp1 UL16 binding protein 1 multiple interactions
increases expression		 ISO Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein		 CTD PMID:21499124 PMID:21951556 NCBI chr 1:1,694,255...1,716,160 JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
Gefitinib results in decreased expression of VEGFA mRNA; Gefitinib results in decreased expression of VEGFA protein
gefitinib results in decreased expression of VEGFA protein		 CTD PMID:15660382 PMID:18424623 PMID:35317323 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vim vimentin multiple interactions ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein] CTD PMID:23255615 PMID:33248157 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 affects response to substance ISO XRCC1 protein polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701 		JBrowse link
G Zc3h3 zinc finger CCCH type containing 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA CTD PMID:20935109 NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451 		JBrowse link
Ku-0063794 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO Ku 0063794 results in decreased phosphorylation of AKT1 protein CTD PMID:22885370 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:22415236 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation		 ISO [Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of RPS6 protein
Ku 0063794 results in decreased phosphorylation of RPS6 protein		 CTD PMID:22415236 PMID:22885370 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
linezolid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alas2 5'-aminolevulinate synthase 2 decreases expression EXP Linezolid results in decreased expression of ALAS2 mRNA CTD PMID:21296123 NCBI chr  X:19,463,146...19,486,526
Ensembl chr  X:19,463,171...19,486,519 		JBrowse link
G Camkv CaM kinase-like vesicle-associated decreases expression EXP Linezolid results in decreased expression of CAMKV mRNA CTD PMID:21296123 NCBI chr 8:108,626,821...108,641,169
Ensembl chr 8:108,626,821...108,641,169 		JBrowse link
G Cdc25b cell division cycle 25B decreases expression EXP Linezolid results in decreased expression of CDC25B mRNA CTD PMID:21296123 NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272 		JBrowse link
G Cfap77 cilia and flagella associated protein 77 decreases expression EXP Linezolid results in decreased expression of CFAP77 mRNA CTD PMID:21296123 NCBI chr 3:12,258,453...12,381,319
Ensembl chr 3:12,258,453...12,381,319 		JBrowse link
G Cib2 calcium and integrin binding family member 2 decreases expression EXP Linezolid results in decreased expression of CIB2 mRNA CTD PMID:21296123 NCBI chr 8:54,930,265...54,947,157 JBrowse link
G Crym crystallin, mu decreases expression EXP Linezolid results in decreased expression of CRYM mRNA CTD PMID:21296123 NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633 		JBrowse link
G Csad cysteine sulfinic acid decarboxylase decreases expression EXP Linezolid results in decreased expression of CSAD mRNA CTD PMID:21296123 NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615 		JBrowse link
G Dars2 aspartyl-tRNA synthetase 2 (mitochondrial) decreases expression EXP Linezolid results in decreased expression of DARS2 mRNA CTD PMID:21296123 NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934 		JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 decreases expression EXP Linezolid results in decreased expression of HBA-A2 mRNA CTD PMID:21296123 NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 		JBrowse link
G Hbb hemoglobin subunit beta decreases expression EXP Linezolid results in decreased expression of HBB mRNA CTD PMID:21296123 NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012 		JBrowse link
G IgG-2a gamma-2a immunoglobulin heavy chain decreases expression EXP Linezolid results in decreased expression of IGG-2A mRNA CTD PMID:21296123
G Kifc1 kinesin family member C1 decreases expression EXP Linezolid results in decreased expression of KIFC1 mRNA CTD PMID:21296123 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105 		JBrowse link
G Maoa monoamine oxidase A decreases activity ISO Linezolid results in decreased activity of MAOA protein CTD PMID:33913699 NCBI chr  X:6,032,172...6,098,308
Ensembl chr  X:6,030,795...6,099,593 		JBrowse link
G Maob monoamine oxidase B decreases activity ISO Linezolid results in decreased activity of MAOB protein CTD PMID:33913699 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression EXP Linezolid results in decreased expression of MKI67 mRNA CTD PMID:21296123 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mlc1 modulator of VRAC current 1 decreases expression EXP Linezolid results in decreased expression of MLC1 mRNA CTD PMID:21296123 NCBI chr 7:120,046,705...120,067,049
Ensembl chr 7:120,046,705...120,067,049 		JBrowse link
G Phlda3 pleckstrin homology-like domain, family A, member 3 decreases expression EXP Linezolid results in decreased expression of PHLDA3 mRNA CTD PMID:21296123 NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335 		JBrowse link
G Prcp prolylcarboxypeptidase decreases expression EXP Linezolid results in decreased expression of PRCP mRNA CTD PMID:21296123 NCBI chr 1:146,931,487...146,983,891
Ensembl chr 1:146,930,561...146,984,530 		JBrowse link
G Prtg protogenin decreases expression EXP Linezolid results in decreased expression of PRTG mRNA CTD PMID:21296123 NCBI chr 8:73,548,440...73,657,945
Ensembl chr 8:73,548,466...73,653,259 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 decreases expression EXP Linezolid results in decreased expression of SLC22A8 mRNA CTD PMID:21296123 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Stac3 SH3 and cysteine rich domain 3 decreases expression EXP Linezolid results in decreased expression of STAC3 mRNA CTD PMID:21296123 NCBI chr 7:63,343,078...63,350,590
Ensembl chr 7:63,343,186...63,350,589 		JBrowse link
G Trip13 thyroid hormone receptor interactor 13 decreases expression EXP Linezolid results in decreased expression of TRIP13 mRNA CTD PMID:21296123 NCBI chr 1:29,357,093...29,402,078
Ensembl chr 1:29,357,130...29,402,074 		JBrowse link
G Zfyve19 zinc finger FYVE-type containing 19 decreases expression EXP Linezolid results in decreased expression of ZFYVE19 mRNA CTD PMID:21296123 NCBI chr 3:106,195,779...106,203,969
Ensembl chr 3:106,195,899...106,203,969 		JBrowse link
linsidomine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca5 ATP binding cassette subfamily A member 5 increases oxidation EXP linsidomine results in increased oxidation of ABCA5 protein CTD PMID:28086193 NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976 		JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases oxidation EXP linsidomine results in increased oxidation of ACP5 protein CTD PMID:28086193 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929 		JBrowse link
G Agrn agrin increases oxidation EXP linsidomine results in increased oxidation of AGRN protein CTD PMID:28086193 NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases metabolic processing
increases phosphorylation
multiple interactions		 ISO
EXP		 linsidomine results in increased metabolism of AKT1 protein
linsidomine results in increased phosphorylation of AKT1 protein
wortmannin inhibits the reaction [linsidomine results in increased phosphorylation of AKT1 protein]
linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]		 CTD PMID:17302912 PMID:19682478 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ap2a2 adaptor related protein complex 2 subunit alpha 2 increases oxidation EXP linsidomine results in increased oxidation of AP2A2 protein CTD PMID:28086193 NCBI chr 1:196,652,315...196,725,609
Ensembl chr 1:196,652,337...196,725,603 		JBrowse link
G Apba1 amyloid beta precursor protein binding family A member 1 increases oxidation EXP linsidomine results in increased oxidation of APBA1 protein CTD PMID:28086193 NCBI chr 1:221,363,769...221,569,496
Ensembl chr 1:221,363,778...221,566,553 		JBrowse link
G Apob apolipoprotein B increases oxidation EXP linsidomine results in increased oxidation of APOB protein CTD PMID:28086193 NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497 		JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 increases oxidation EXP linsidomine results in increased oxidation of ARNT2 protein CTD PMID:28086193 NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153 		JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO linsidomine results in increased expression of ATF4 mRNA CTD PMID:21703327 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Avp arginine vasopressin increases expression EXP linsidomine results in increased expression of AVP mRNA CTD PMID:10460269 NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425 		JBrowse link
G Avpr1b arginine vasopressin receptor 1B increases oxidation EXP linsidomine results in increased oxidation of AVPR1B protein CTD PMID:28086193 NCBI chr13:43,046,960...43,057,110
Ensembl chr13:43,046,267...43,057,792 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO linsidomine results in increased expression of BAX
Selegiline inhibits the reaction [linsidomine results in increased expression of BAX protein]
MT1A inhibits the reaction [linsidomine results in increased expression of BAX]		 CTD PMID:12880480 PMID:16291239 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions		 ISO linsidomine results in decreased expression of BCL2; linsidomine results in decreased expression of BCL2 protein
[linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 mRNA; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 protein; Selegiline inhibits the reaction [linsidomine results in decreased expression of BCL2 protein]
MT1A inhibits the reaction [linsidomine results in decreased expression of BCL2]; Plant Extracts inhibits the reaction [linsidomine results in decreased expression of BCL2 protein]		 CTD PMID:7706495 PMID:12880480 PMID:16291239 PMID:23174672 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Brca2 BRCA2, DNA repair associated increases oxidation EXP linsidomine results in increased oxidation of BRCA2 protein CTD PMID:28086193 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567 		JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C multiple interactions ISO [linsidomine co-treated with Peroxynitrous Acid] results in increased nitrosation of CACNA1C protein CTD PMID:17551092 NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648 		JBrowse link
G Cacna1e calcium voltage-gated channel subunit alpha1 E increases oxidation EXP linsidomine results in increased oxidation of CACNA1E protein CTD PMID:28086193 NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H increases oxidation EXP linsidomine results in increased oxidation of CACNA1H protein CTD PMID:28086193 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376 		JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 increases oxidation EXP linsidomine results in increased oxidation of CACNB2 protein CTD PMID:28086193 NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases response to substance EXP CALCA protein results in increased susceptibility to linsidomine CTD PMID:8581270 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105 		JBrowse link
G Carm1 coactivator-associated arginine methyltransferase 1 increases oxidation EXP linsidomine results in increased oxidation of CARM1 protein CTD PMID:28086193 NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689 		JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
increases expression
increases cleavage		 ISO
EXP		 linsidomine results in increased activity of CASP3 protein
Melatonin inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; MT1A inhibits the reaction [linsidomine results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [linsidomine results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [linsidomine results in increased expression of CASP3 protein modified form]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 protein]; Ubiquinone inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]
linsidomine results in increased expression of CASP3 mRNA; linsidomine results in increased expression of CASP3 protein; linsidomine results in increased expression of CASP3 protein modified form		 CTD PMID:12880480 PMID:15686499 PMID:16291239 PMID:19038279 PMID:23174672 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions ISO linsidomine results in decreased activity of and results in decreased expression of CAT protein; Plant Extracts inhibits the reaction [linsidomine results in decreased activity of and results in decreased expression of CAT protein]
CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 mRNA]; CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 protein]		 CTD PMID:12600834 PMID:23174672 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression		 ISO CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 mRNA]; CAT protein inhibits the reaction [linsidomine results in decreased expression of CCND1 protein]
linsidomine results in decreased expression of CCND1 mRNA; linsidomine results in decreased expression of CCND1 protein		 CTD PMID:12600834 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cep83 centrosomal protein 83 increases oxidation EXP linsidomine results in increased oxidation of CEP83 protein CTD PMID:28086193 NCBI chr 7:29,280,358...29,389,574
Ensembl chr 7:29,280,419...29,389,574 		JBrowse link
G Cep95 centrosomal protein 95 increases oxidation EXP linsidomine results in increased oxidation of CEP95 protein CTD PMID:28086193 NCBI chr10:91,732,111...91,760,095
Ensembl chr10:91,732,111...91,760,092 		JBrowse link
G Cldn5 claudin 5 decreases expression ISO linsidomine results in decreased expression of CLDN5 protein CTD PMID:34391839 NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992 		JBrowse link
G Clrn1 clarin 1 increases oxidation EXP linsidomine results in increased oxidation of CLRN1 protein CTD PMID:28086193 NCBI chr 2:143,084,030...143,130,948
Ensembl chr 2:143,084,030...143,130,948 		JBrowse link
G Clu clusterin increases oxidation EXP linsidomine results in increased oxidation of CLU protein CTD PMID:28086193 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315 		JBrowse link
G Crh corticotropin releasing hormone multiple interactions
increases expression		 EXP CRH protein affects the reaction [linsidomine results in increased secretion of POMC protein alternative form]
linsidomine results in increased expression of CRH mRNA		 CTD PMID:10460269 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919 		JBrowse link
G Crhr1 corticotropin releasing hormone receptor 1 increases expression EXP linsidomine results in increased expression of CRHR1 mRNA CTD PMID:10460269 NCBI chr10:89,040,203...89,083,481
Ensembl chr10:89,040,203...89,083,481 		JBrowse link
G Cttnbp2 cortactin binding protein 2 increases oxidation EXP linsidomine results in increased oxidation of CTTNBP2 protein CTD PMID:28086193 NCBI chr 4:46,800,975...46,964,681
Ensembl chr 4:46,800,981...46,964,631 		JBrowse link
G Cycs cytochrome c, somatic affects localization
multiple interactions		 ISO linsidomine affects the localization of CYCS protein
Selegiline inhibits the reaction [linsidomine affects the localization of CYCS protein]		 CTD PMID:12880480 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO linsidomine results in increased expression of DDIT3 mRNA CTD PMID:21703327 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddx52 DExD-box helicase 52 increases oxidation EXP linsidomine results in increased oxidation of DDX52 protein CTD PMID:28086193 NCBI chr10:68,824,594...68,847,400
Ensembl chr10:68,824,645...68,848,266 		JBrowse link
G Dlgap4 DLG associated protein 4 increases oxidation EXP linsidomine results in increased oxidation of DLGAP4 protein CTD PMID:28086193 NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490 		JBrowse link
G Dnah7 dynein, axonemal, heavy chain 7 increases oxidation EXP linsidomine results in increased oxidation of DNAH7 protein CTD PMID:28086193 NCBI chr 9:54,960,235...55,266,529
Ensembl chr 9:54,960,440...55,262,297 		JBrowse link
G Dnmt1 DNA methyltransferase 1 increases oxidation EXP linsidomine results in increased oxidation of DNMT1 protein CTD PMID:28086193 NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659 		JBrowse link
G Dscam DS cell adhesion molecule increases oxidation EXP linsidomine results in increased oxidation of DSCAM protein CTD PMID:28086193 NCBI chr11:35,921,924...36,507,100
Ensembl chr11:35,926,896...36,507,415 		JBrowse link
G E2f2 E2F transcription factor 2 decreases activity ISO linsidomine results in decreased activity of E2F2 protein CTD PMID:12600834 NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217 		JBrowse link
G Eaf2 ELL associated factor 2 increases oxidation EXP linsidomine results in increased oxidation of EAF2 protein CTD PMID:28086193 NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation ISO linsidomine results in increased phosphorylation of EIF2AK3 protein CTD PMID:21703327 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation ISO linsidomine results in increased phosphorylation of EIF2S1 protein CTD PMID:21703327 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Ephx2 epoxide hydrolase 2 increases oxidation EXP linsidomine results in increased oxidation of EPHX2 protein CTD PMID:28086193 NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615 		JBrowse link
G Evl Enah/Vasp-like increases oxidation EXP linsidomine results in increased oxidation of EVL protein CTD PMID:28086193 NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344 		JBrowse link
G Fam221b family with sequence similarity 221, member B increases oxidation EXP linsidomine results in increased oxidation of FAM221B protein CTD PMID:28086193 NCBI chr 5:57,910,346...57,919,562
Ensembl chr 5:57,910,352...57,919,367 		JBrowse link
G Faslg Fas ligand multiple interactions ISO [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter] CTD PMID:10811113 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fasn fatty acid synthase increases oxidation EXP linsidomine results in increased oxidation of FASN protein CTD PMID:28086193 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261 		JBrowse link
G Fra10ac1 FRA10A associated CGG repeat 1 increases oxidation EXP linsidomine results in increased oxidation of FRA10AC1 protein CTD PMID:28086193 NCBI chr 1:235,969,071...236,001,074
Ensembl chr 1:235,969,112...236,001,210 		JBrowse link
G Gabra5 gamma-aminobutyric acid type A receptor subunit alpha 5 increases oxidation EXP linsidomine results in increased oxidation of GABRA5 protein CTD PMID:28086193 NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917 		JBrowse link
G Glg1 golgi glycoprotein 1 increases oxidation EXP linsidomine results in increased oxidation of GLG1 protein CTD PMID:28086193 NCBI chr19:39,124,892...39,224,178
Ensembl chr19:39,124,641...39,224,178 		JBrowse link
G Golga4 golgin A4 increases oxidation EXP linsidomine results in increased oxidation of GOLGA4 protein CTD PMID:28086193 NCBI chr 8:118,208,200...118,285,003 JBrowse link
G Grm7 glutamate metabotropic receptor 7 increases oxidation EXP linsidomine results in increased oxidation of GRM7 protein CTD PMID:28086193 NCBI chr 4:143,730,862...144,613,230
Ensembl chr 4:143,731,259...144,612,344 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression EXP linsidomine results in increased expression of GSTA2; linsidomine results in increased expression of GSTA2 protein CTD PMID:12446173 PMID:15357004 NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798 		JBrowse link
G Gucy2d guanylate cyclase 2D, retinal increases oxidation EXP linsidomine results in increased oxidation of GUCY2E protein CTD PMID:28086193 NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067 		JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases oxidation EXP linsidomine results in increased oxidation of HADHA protein CTD PMID:28086193 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869 		JBrowse link
G Hgs hepatocyte growth factor-regulated tyrosine kinase substrate increases oxidation EXP linsidomine results in increased oxidation of HGS protein CTD PMID:28086193 NCBI chr10:105,739,617...105,757,838
Ensembl chr10:105,739,296...105,757,835 		JBrowse link
G Hist1h2bg histone cluster 1, H2bg increases oxidation EXP linsidomine results in increased oxidation of HIST1H2BG protein CTD PMID:28086193 NCBI chr17:41,571,278...41,571,658
Ensembl chr17:41,571,210...41,571,896 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression		 ISO [linsidomine co-treated with Nitroprusside] results in increased expression of HMOX1 mRNA; [linsidomine co-treated with S-Nitrosoglutathione] results in increased expression of HMOX1 mRNA
linsidomine results in increased expression of HMOX1 mRNA		 CTD PMID:8764571 PMID:10423162 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hnrnpm heterogeneous nuclear ribonucleoprotein M increases oxidation EXP linsidomine results in increased oxidation of HNRNPM protein CTD PMID:28086193 NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762 		JBrowse link
G Hormad1 HORMA domain containing 1 increases oxidation EXP linsidomine results in increased oxidation of HORMAD1 protein CTD PMID:28086193 NCBI chr 2:183,115,815...183,152,383
Ensembl chr 2:183,116,716...183,152,383 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases secretion		 ISO TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of IL6 protein] CTD PMID:29175419 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ilk integrin-linked kinase increases oxidation EXP linsidomine results in increased oxidation of ILK protein CTD PMID:28086193 NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140 		JBrowse link
G Ins1 insulin 1 multiple interactions ISO linsidomine inhibits the reaction [INS1 protein binds to PIK3R1 protein]; linsidomine inhibits the reaction [INS1 protein results in increased activity of PIK3R1 protein]; linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]; linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of IRS1 protein] CTD PMID:19682478 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Insr insulin receptor multiple interactions
increases metabolic processing		 ISO linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]
linsidomine results in increased metabolism of INSR protein		 CTD PMID:19682478 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883 		JBrowse link
G Iqsec3 IQ motif and Sec7 domain ArfGEF 3 increases oxidation EXP linsidomine results in increased oxidation of IQSEC3 protein CTD PMID:28086193 NCBI chr 4:154,610,933...154,707,310
Ensembl chr 4:154,610,934...154,707,310 		JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions ISO linsidomine inhibits the reaction [INS1 protein results in increased phosphorylation of IRS1 protein]; linsidomine results in increased metabolism of and results in decreased expression of IRS1 protein CTD PMID:19682478 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Itpr1 inositol 1,4,5-trisphosphate receptor, type 1 multiple interactions
increases expression		 ISO Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Dactinomycin inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA] CTD PMID:17241155 NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491 		JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 increases oxidation EXP linsidomine results in increased oxidation of ITPR3 protein CTD PMID:28086193 NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337 		JBrowse link
G Kat6a lysine acetyltransferase 6A increases oxidation EXP linsidomine results in increased oxidation of KAT6A protein CTD PMID:28086193 NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects response to substance ISO KEAP1 mRNA affects the susceptibility to linsidomine CTD PMID:16092930 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Khdrbs2 KH RNA binding domain containing, signal transduction associated 2 increases oxidation EXP linsidomine results in increased oxidation of KHDRBS2 protein CTD PMID:28086193 NCBI chr 9:34,447,023...34,953,684
Ensembl chr 9:34,447,056...34,915,530 		JBrowse link
G Klk8 kallikrein related-peptidase 8 increases oxidation EXP linsidomine results in increased oxidation of KLK8 protein CTD PMID:28086193 NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation		 ISO bosutinib affects the reaction [linsidomine results in increased phosphorylation of MAPK8 protein] CTD PMID:34519134 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mprip myosin phosphatase Rho interacting protein increases oxidation EXP linsidomine results in increased oxidation of MPRIP protein CTD PMID:28086193 NCBI chr10:44,453,929...44,569,442
Ensembl chr10:44,453,929...44,569,118 		JBrowse link
G Mt1 metallothionein 1 multiple interactions ISO MT1A inhibits the reaction [linsidomine results in decreased expression of BCL2]; MT1A inhibits the reaction [linsidomine results in increased activity of CASP3 protein]; MT1A inhibits the reaction [linsidomine results in increased expression of BAX] CTD PMID:16291239 NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 		JBrowse link
G Mtfr1 mitochondrial fission regulator 1 increases oxidation EXP linsidomine results in increased oxidation of MTFR1 protein CTD PMID:28086193 NCBI chr 2:101,678,331...101,713,547
Ensembl chr 2:101,679,265...101,713,544 		JBrowse link
G Mtor mechanistic target of rapamycin kinase increases oxidation EXP linsidomine results in increased oxidation of MTOR protein CTD PMID:28086193 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Mybpc3 myosin binding protein C3 increases oxidation EXP linsidomine results in increased oxidation of MYBPC3 protein CTD PMID:28086193 NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:77,095,252...77,113,405 		JBrowse link
G Nat1 N-acetyltransferase 1 decreases activity ISO linsidomine results in decreased activity of NAT1 protein CTD PMID:14672957 NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520 		JBrowse link
G Nbr1 NBR1, autophagy cargo receptor increases oxidation EXP linsidomine results in increased oxidation of NBR1 protein CTD PMID:28086193 NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412 		JBrowse link
G Nf1 neurofibromin 1 increases oxidation EXP linsidomine results in increased oxidation of NF1 protein CTD PMID:28086193 NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
decreases response to substance		 ISO
EXP		 [linsidomine results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine
linsidomine results in increased localization of and results in increased activity of NFE2L2 protein
NFE2L2 results in decreased susceptibility to linsidomine
1,2-dithiol-3-thione promotes the reaction [NFE2L2 results in decreased susceptibility to linsidomine]
NFE2L2 protein results in decreased susceptibility to linsidomine		 CTD PMID:12446173 PMID:16092930 PMID:18367636 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
increases oxidation		 EXP linsidomine results in increased expression of NOS1 mRNA
linsidomine results in increased oxidation of NOS1 protein		 CTD PMID:19038279 PMID:28086193 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945 		JBrowse link
G Nos2 nitric oxide synthase 2 increases expression
multiple interactions		 ISO linsidomine results in increased expression of NOS2 protein
[linsidomine results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites; [Plant Extracts inhibits the reaction [linsidomine results in increased expression of NOS2 protein]] which results in decreased chemical synthesis of Nitrites; Plant Extracts inhibits the reaction [linsidomine results in increased expression of NOS2 protein]		 CTD PMID:23174672 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 increases expression EXP linsidomine results in increased expression of NR4A1 mRNA CTD PMID:10460269 NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297 		JBrowse link
G Oma1 OMA1 zinc metallopeptidase increases oxidation EXP linsidomine results in increased oxidation of OMA1 protein CTD PMID:28086193 NCBI chr 5:118,083,728...118,136,980
Ensembl chr 5:118,083,728...118,136,980 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
decreases activity
decreases folding
decreases expression		 ISO Selegiline inhibits the reaction [linsidomine results in decreased expression of PARP1 protein]
linsidomine results in increased cleavage of PARP1 protein
linsidomine results in decreased activity of PARP1 protein
[bosutinib co-treated with linsidomine] affects the expression of PARP1 protein; bosutinib affects the reaction [linsidomine results in increased cleavage of PARP1 protein]; linsidomine inhibits the reaction [PARP1 protein binds to Zinc]; linsidomine results in decreased activity of and results in increased nitrosation of PARP1 protein
linsidomine results in decreased folding of PARP1 protein		 CTD PMID:12880480 PMID:31152818 PMID:34519134 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO linsidomine results in decreased expression of PCNA protein CTD PMID:12600834 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pds5a PDS5 cohesin associated factor A increases oxidation EXP linsidomine results in increased oxidation of PDS5A protein CTD PMID:28086193 NCBI chr14:42,551,653...42,651,074
Ensembl chr14:42,552,647...42,648,669 		JBrowse link
G Pepd peptidase D multiple interactions ISO linsidomine results in increased phosphorylation of and results in increased activity of PEPD protein CTD PMID:16167338 NCBI chr 1:87,536,650...87,681,233
Ensembl chr 1:87,536,609...87,681,231 		JBrowse link
G Per2 period circadian regulator 2 decreases response to substance ISO PER2 protein mutant form results in decreased susceptibility to linsidomine CTD PMID:25628599 NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459 		JBrowse link
G Pi4ka phosphatidylinositol 4-kinase alpha increases oxidation EXP linsidomine results in increased oxidation of PI4KA protein CTD PMID:28086193 NCBI chr11:83,609,136...83,726,876
Ensembl chr11:83,609,069...83,724,080 		JBrowse link
G Pif1 PIF1 5'-to-3' DNA helicase increases oxidation EXP linsidomine results in increased oxidation of PIF1 protein CTD PMID:28086193 NCBI chr 8:66,110,641...66,120,202
Ensembl chr 8:66,111,072...66,120,200 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO linsidomine inhibits the reaction [INS1 protein binds to PIK3R1 protein]; linsidomine inhibits the reaction [INS1 protein results in increased activity of PIK3R1 protein] CTD PMID:19682478 NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Plb1 phospholipase B1 increases oxidation EXP linsidomine results in increased oxidation of PLB1 protein CTD PMID:28086193 NCBI chr 6:24,087,051...24,227,167
Ensembl chr 6:24,089,214...24,210,117 		JBrowse link
G Plekhg5 pleckstrin homology and RhoGEF domain containing G5 increases oxidation EXP linsidomine results in increased oxidation of PLEKHG5 protein CTD PMID:28086193 NCBI chr 5:162,577,999...162,621,518
Ensembl chr 5:162,578,071...162,621,513 		JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases secretion		 EXP CRH protein affects the reaction [linsidomine results in increased secretion of POMC protein alternative form] CTD PMID:10460269 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664 		JBrowse link
G Ppp1r37 protein phosphatase 1, regulatory subunit 37 increases oxidation EXP linsidomine results in increased oxidation of PPP1R37 protein CTD PMID:28086193 NCBI chr 1:79,180,794...79,212,612
Ensembl chr 1:79,180,793...79,212,612 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions EXP [linsidomine co-treated with Staurosporine] results in decreased expression of PRKCA protein; Staurosporine inhibits the reaction [linsidomine results in increased phosphorylation of PRKCA protein] CTD PMID:11994256 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases expression
multiple interactions		 ISO linsidomine results in increased expression of PRKN protein
Selegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein]		 CTD PMID:12880480 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Pten phosphatase and tensin homolog increases oxidation EXP linsidomine results in increased oxidation of PTEN protein CTD PMID:17302912 NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838 		JBrowse link
G Rab29 RAB29, member RAS oncogene family increases oxidation EXP linsidomine results in increased oxidation of RAB29 protein CTD PMID:28086193 NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417 		JBrowse link
G Ran RAN, member RAS oncogene family increases oxidation EXP linsidomine results in increased oxidation of RAN protein CTD PMID:28086193 NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation ISO linsidomine results in decreased phosphorylation of RB1 protein CTD PMID:12600834 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [linsidomine affects the activity of RELA protein]; linsidomine affects the localization of and affects the activity of RELA protein CTD PMID:29175419 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rexo5 RNA exonuclease 5 increases oxidation EXP linsidomine results in increased oxidation of REXO5 protein CTD PMID:28086193 NCBI chr 1:174,168,633...174,264,526
Ensembl chr 1:174,168,694...174,241,486 		JBrowse link
G Ryr2 ryanodine receptor 2 increases oxidation EXP linsidomine results in increased oxidation of RYR2 protein CTD PMID:28086193 NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142 		JBrowse link
G Sclt1 sodium channel and clathrin linker 1 increases oxidation EXP linsidomine results in increased oxidation of SCLT1 protein CTD PMID:28086193 NCBI chr 2:124,605,445...124,763,964
Ensembl chr 2:124,605,658...124,764,065 		JBrowse link
G Scn8a sodium voltage-gated channel alpha subunit 8 increases oxidation EXP linsidomine results in increased oxidation of SCN8A protein CTD PMID:28086193 NCBI chr 7:131,982,152...132,156,075
Ensembl chr 7:131,982,480...132,151,292 		JBrowse link
G Secisbp2 SECIS binding protein 2 increases oxidation EXP linsidomine results in increased oxidation of SECISBP2 protein CTD PMID:28086193 NCBI chr17:13,538,513...13,569,573
Ensembl chr17:13,538,513...13,569,523 		JBrowse link
G Sfrp4 secreted frizzled-related protein 4 increases oxidation EXP linsidomine results in increased oxidation of SFRP4 protein CTD PMID:28086193 NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736 		JBrowse link
G Slc12a2 solute carrier family 12 member 2 multiple interactions
increases activity		 EXP linsidomine results in increased phosphorylation of and results in increased expression of SLC12A2 protein
linsidomine results in increased activity of SLC12A2 protein		 CTD PMID:25817889 NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440 		JBrowse link
G Smc1a structural maintenance of chromosomes 1A increases oxidation EXP linsidomine results in increased oxidation of SMC1A protein CTD PMID:28086193 NCBI chr  X:21,103,323...21,148,053
Ensembl chr  X:21,103,282...21,148,056 		JBrowse link
G Snca synuclein alpha increases expression
multiple interactions		 ISO linsidomine results in increased expression of SNCA protein
Selegiline inhibits the reaction [linsidomine results in increased expression of SNCA protein]		 CTD PMID:12880480 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO linsidomine results in decreased activity of and results in decreased expression of SOD1 protein; Plant Extracts inhibits the reaction [linsidomine results in decreased activity of and results in decreased expression of SOD1 protein] CTD PMID:23174672 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases response to substance
increases expression		 ISO Acetylcysteine inhibits the reaction [linsidomine results in increased expression of SOD2 mRNA]; Cysteine inhibits the reaction [linsidomine results in increased expression of SOD2 mRNA]
SOD2 protein results in increased susceptibility to linsidomine		 CTD PMID:9741582 PMID:10511315 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Speg striated muscle enriched protein kinase increases oxidation EXP linsidomine results in increased oxidation of SPEG protein CTD PMID:28086193 NCBI chr 9:76,865,714...76,923,170
Ensembl chr 9:76,865,754...76,923,144 		JBrowse link
G Svep1 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 increases oxidation EXP linsidomine results in increased oxidation of SVEP1 protein CTD PMID:28086193 NCBI chr 5:72,811,200...72,988,813
Ensembl chr 5:72,811,410...72,988,525 		JBrowse link
G Synrg synergin, gamma increases oxidation EXP linsidomine results in increased oxidation of SYNRG protein CTD PMID:28086193 NCBI chr10:68,848,828...68,931,252
Ensembl chr10:68,849,642...68,931,250 		JBrowse link
G Sytl4 synaptotagmin-like 4 increases oxidation EXP linsidomine results in increased oxidation of SYTL4 protein CTD PMID:28086193 NCBI chr  X:97,135,500...97,185,867
Ensembl chr  X:97,135,500...97,185,854 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases activity
decreases expression		 EXP 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [linsidomine results in decreased expression of TGFB1 mRNA]; 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide inhibits the reaction [linsidomine results in decreased expression of TGFB1 protein]
linsidomine results in increased activity of TGFB1 protein
linsidomine results in decreased expression of TGFB1 mRNA; linsidomine results in decreased expression of TGFB1 protein		 CTD PMID:11994256 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of IL6 protein]; TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of TNF protein] CTD PMID:29175419 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor increases secretion
multiple interactions		 ISO linsidomine results in increased secretion of TNF protein
TLR4 gene mutant form inhibits the reaction [linsidomine results in increased secretion of TNF protein]		 CTD PMID:29175419 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Trim40 tripartite motif-containing 40 increases oxidation EXP linsidomine results in increased oxidation of TRIM40 protein CTD PMID:28086193 NCBI chr20:1,676,188...1,685,906
Ensembl chr20:1,676,270...1,685,214 		JBrowse link
G Trpm1 transient receptor potential cation channel, subfamily M, member 1 increases oxidation EXP linsidomine results in increased oxidation of TRPM1 protein CTD PMID:28086193 NCBI chr 1:117,718,896...117,835,434
Ensembl chr 1:117,718,896...117,834,605 		JBrowse link
G Trpm7 transient receptor potential cation channel, subfamily M, member 7 increases oxidation EXP linsidomine results in increased oxidation of TRPM7 protein CTD PMID:28086193 NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190 		JBrowse link
G Unc13a unc-13 homolog A increases oxidation EXP linsidomine results in increased oxidation of UNC13A protein CTD PMID:28086193 NCBI chr16:18,336,229...18,381,811
Ensembl chr16:18,336,229...18,381,872 		JBrowse link
G Vgf VGF nerve growth factor inducible increases oxidation EXP linsidomine results in increased oxidation of VGF protein CTD PMID:28086193 NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341 		JBrowse link
G Vim vimentin increases oxidation EXP linsidomine results in increased oxidation of VIM protein CTD PMID:28086193 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
G Wdr7 WD repeat domain 7 increases oxidation EXP linsidomine results in increased oxidation of WDR7 protein CTD PMID:28086193 NCBI chr18:57,165,482...57,448,568
Ensembl chr18:57,165,488...57,448,540 		JBrowse link
G Whrn whirlin increases oxidation EXP linsidomine results in increased oxidation of WHRN protein CTD PMID:28086193 NCBI chr 5:76,828,308...76,911,945
Ensembl chr 5:76,828,301...76,912,223 		JBrowse link
G Ythdc1 YTH N6-methyladenosine RNA binding protein C1 increases oxidation EXP linsidomine results in increased oxidation of YTHDC1 protein CTD PMID:28086193 NCBI chr14:21,185,438...21,215,934
Ensembl chr14:21,185,440...21,216,028 		JBrowse link
G Zfp148 zinc finger protein 148 increases oxidation EXP linsidomine results in increased oxidation of ZFP148 protein CTD PMID:28086193 NCBI chr11:67,276,455...67,385,803
Ensembl chr11:67,281,707...67,385,772 		JBrowse link
G Zfp518a zinc finger protein 518A increases oxidation EXP linsidomine results in increased oxidation of ZFP518A protein CTD PMID:28086193 NCBI chr 1:239,719,305...239,744,978
Ensembl chr 1:239,719,505...239,744,979 		JBrowse link
LY294002 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A decreases expression ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 protein CTD PMID:23466342 PMID:27888070 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B multiple interactions
decreases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[NFKB1 protein binds to RELA protein] which results in increased expression of ABCB1B mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Curcumin results in decreased expression of ABCB1B protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1B protein		 CTD PMID:18006147 NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC1 protein CTD PMID:27888070 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [erucin results in increased expression of ABCC2 mRNA] CTD PMID:15896333 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc5 ATP binding cassette subfamily C member 5 decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC5 protein CTD PMID:23994249 NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] CTD PMID:21712253 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] CTD PMID:16849647 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased expression of ACTA2 protein] CTD PMID:33895847 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Acvr2b activin A receptor type 2B multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ACVR2B mRNA] CTD PMID:12710931 NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458 		JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein] CTD PMID:19356108 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564 		JBrowse link
G Adra1a adrenoceptor alpha 1A multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose] CTD PMID:15550506 NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased expression of AGER protein] CTD PMID:21807062 NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078 		JBrowse link
G Agt angiotensinogen multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased expression of POSTN mRNA] CTD PMID:15121739 PMID:16325820 PMID:23300732 PMID:25398788 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Ahr aryl hydrocarbon receptor increases expression
multiple interactions
decreases expression		 EXP
ISO		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased activity of AHR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AHR mRNA		 CTD PMID:22406437 PMID:27020609 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] CTD PMID:17640564 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 decreases expression ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein CTD PMID:23994249 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] CTD PMID:21787718 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases expression
decreases reaction
decreases phosphorylation
multiple interactions
decreases expression
decreases activity		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AKT1 protein
LY294002 inhibits the reaction [estrogen increases phosphorylation of Akt1 protein] in rat uterus
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Glucose co-treated with Calcitriol] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol F results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Chlorpyrifos results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [etoxazole results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LEPR gene mutant form results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mercuric Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Methylmercury Compounds results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 inhibits the reaction [triethylene glycol dimethacrylate results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [notoginsenoside R1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phospholipids results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [Okadaic Acid results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [RELN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [SMARCA4A protein inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Temozolomide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of and results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with HRAS protein] results in decreased phosphorylation of AKT1 protein; [Butyrates co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of [PDK1 protein binds to AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [1,3-dichloro-2-propanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-hydroxyestradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[FGF7 protein results in increased phosphorylation of AKT1 protein] which results in increased expression of ESR1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[HSPA1A protein co-treated with Formaldehyde] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[MIR21 mRNA results in decreased susceptibility to Cisplatin] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Rosiglitazone co-treated with IAPP protein] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acetylcysteine results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Atrazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Endosulfan results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ethanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [hemistepsin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [KMUP 1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Phosphates results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Polychlorinated Biphenyls analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [propazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PTK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [spiraeoside inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Temozolomide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [terbutylazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Trichloroethylene results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ursodeoxycholic Acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Zinc Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [celastrol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [di-n-propyldithiocarbamate results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [fosbretabulin analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [kahweol results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Oligopeptides analog results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [polyphenon E results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [ZH-2 compound results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Benzo(a)pyrene] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Estradiol] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Quercetin] results in decreased phosphorylation of AKT1 protein; [Cannabidiol co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Formaldehyde co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; [PDK1 protein binds to AKT1 protein] inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of RPS6 protein]; [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [sodium arsenite co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; arsenic disulfide promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Arsenic Trioxide promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Cisplatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; kahweol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; polyphenon E promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Tamoxifen promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[5-aminoisoquinolinone co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Capsaicin co-treated with Oxygen deficiency co-treated with Oxygen] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cilomilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deuterohemin-alanyl-histidyl-threonyl-valyl-glutamyl-lysine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [diallyl trisulfide inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxepin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rh4 inhibits the reaction [Alloxan results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Glucose results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [GRN protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Isoproterenol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [LHCGR protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Mevinphos results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MT2A protein inhibits the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [N(6)-cyclopentyladenosine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Quercetin inhibits the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rhodioloside inhibits the reaction [Colistin results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvianolic acid B results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sevoflurane results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Thapsigargin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Tunicamycin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [[Dithionite co-treated with Glucose deficiency] results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Tunicamycin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of and results in decreased activity of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased phosphorylation of AKT1 protein; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tretinoin] results in decreased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKT1 protein		 CTD
RGD		 PMID:11306697 PMID:11788791 PMID:12438947 PMID:12511591 PMID:12556562 More... RGD:152177689 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1S1 protein CTD PMID:17457363 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677 		JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL protein]] CTD PMID:33450223 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446 		JBrowse link
G Angpt1 angiopoietin 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein results in decreased susceptibility to Doxorubicin] CTD PMID:15763944 NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067 		JBrowse link
G Angpt2 angiopoietin 2 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in decreased expression of BAX protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of BCL2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT2 protein results in increased expression of MKI67 protein] CTD PMID:31838054 NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804 		JBrowse link
G Apln apelin increases expression
multiple interactions
increases secretion		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of APLN mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Eicosapentaenoic Acid results in increased expression of APLN mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased secretion of APLN protein		 CTD PMID:20352620 PMID:21461750 NCBI chr  X:127,180,801...127,213,567
Ensembl chr  X:127,203,823...127,213,391 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [coenzyme Q10 results in decreased susceptibility to APP protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [APP protein modified form results in increased activity of CASP3 protein]		 CTD PMID:16648635 PMID:19741129 PMID:22186599 PMID:28756148 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased expression of AQP3 protein] CTD PMID:16848764 PMID:18214481 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720 		JBrowse link
G Aqp9 aquaporin 9 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in decreased expression of AQP9 mRNA] CTD PMID:20378617 NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395 		JBrowse link
G Ar androgen receptor multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in decreased expression of AR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methoxyacetic acid promotes the reaction [Testosterone results in increased activity of AR protein]] CTD